Peptide News Digest

ADA 2026 Day 2: Retatrutide TRIUMPH-1 Full Data + Lancet TRANSCEND-T2D-1, TRIUMPH-4 OA + TRIUMPH-3 OSA, Arrhythmia Safety Signal, ADA Obesity Standards of Care 2026

ADA Day 2: full retatrutide TRIUMPH-1 + TRIUMPH-4 data, Lancet publishes TRANSCEND-T2D-1, an arrhythmia signal, plus the ADA Obesity Standards of Care.

6 stories · Covering clinical-trials, regulatory, industry

Editor's Note

Saturday belonged to retatrutide. Eli Lilly's triple GLP-1/GIP/glucagon agonist took the Day-2 symposium with the full TRIUMPH-1 obesity dataset (28.3% mean weight loss at 80 weeks, 30.3% in the BMI ≥35 extension at 104 weeks), simultaneous Lancet publication of TRANSCEND-T2D-1 in diabetes (up to 2.0% A1C drop, 46% reaching normal A1C), and the first read on comorbidities at scale: 28.7% weight loss plus 75.8% knee-osteoarthritis pain reduction in TRIUMPH-4, and OSA improvement in TRIUMPH-3. A safety wrinkle landed in the same data: seven of 403 retatrutide patients had arrhythmias and three had major cardiovascular events versus none on placebo, a number STAT flagged the same morning. Off the Lilly stage, the ADA released its inaugural Standards of Care in Overweight and Obesity (34 new recommendations), a parallel event that quietly normalizes obesity drugs as standard-of-care prescribing rather than off-label cosmetic medicine. Cybrexa's CBX-12 ovarian-cancer peptide-drug conjugate and the Cancer-spinout Crossbow Therapeutics held the non-GLP-1 corners of the day.

Clinical Trials

Lilly Retatrutide TRIUMPH-1 Full Phase 3 Data at ADA 2026: 28.3% Weight Loss at 80 Weeks, 30.3% in BMI ≥35 at 104 Weeks, Plus Comorbidity Improvements Across OSA, OA, and T2D

At Saturday's Phase 3 retatrutide symposium, Lilly presented the full TRIUMPH-1 dataset in 2,339 adults with obesity or overweight without diabetes. Mean weight loss reached 28.3% (70.3 lbs) at 12 mg over 80 weeks, with 45.3% of 12 mg patients reaching at least 30% loss; in a BMI ≥35 extension, the 12 mg arm hit 30.3% (85.0 lbs) at 104 weeks. Cardiometabolic side effects included up to 41.0% triglyceride drop, 24.2% non-HDL drop, 12.3 mmHg systolic blood pressure drop, and 24.1 cm waist reduction. The 4 mg dose still produced 19.0% weight loss with discontinuation below placebo.

#retatrutide #triumph-1 #eli-lilly #obesity #phase-3 #ada-2026
Clinical Trials

TRANSCEND-T2D-1 Simultaneously Published in The Lancet: Retatrutide Drives Up to 2.0% A1C Reduction and 16.8% Weight Loss in Type 2 Diabetes, 46% Reaching Normal A1C

The first Phase 3 retatrutide diabetes trial, TRANSCEND-T2D-1, was simultaneously published in The Lancet and presented at the June 6 symposium. In adults with type 2 diabetes inadequately controlled on lifestyle alone, retatrutide produced A1C reductions of up to 2.0 percentage points and weight loss of up to 16.8% (36.6 lbs) at 40 weeks, with up to 46% achieving a normal A1C — a threshold rare in diabetes treatment trials. Systolic blood pressure and lipid markers improved across doses.

#retatrutide #transcend-t2d-1 #eli-lilly #type-2-diabetes #lancet #ada-2026
Clinical Trials

Retatrutide Arrhythmia and MACE Safety Signal at ADA 2026: 7 of 403 Arrhythmias and 3 MACE on Drug Versus None on Placebo

STAT reported June 6 that new safety data presented at ADA showed seven of 403 retatrutide-treated patients experienced arrhythmias and three had major cardiovascular events, compared with none in the placebo group. The signal had been a watch item ahead of ADA because retatrutide adds glucagon-receptor activity to GLP-1 and GIP, raising heart-rate and energy-expenditure mechanisms that have not appeared in the same way for semaglutide or tirzepatide. Lilly's larger TRIUMPH-OUTCOMES cardiovascular trial reads out in 2027.

#retatrutide #safety #arrhythmia #mace #glucagon #ada-2026
Clinical Trials

TRIUMPH-4 Phase 3 in Obesity Plus Knee Osteoarthritis: 28.7% Weight Loss and 75.8% Pain Reduction at 68 Weeks

ADA 2026 brought full TRIUMPH-4 results in adults with obesity and knee osteoarthritis. At the 12 mg dose, mean weight loss reached 28.7% at 68 weeks, and WOMAC pain scores dropped by an average of 4.5 points, a 75.8% reduction. The combination of substantial weight loss with a directly measured pain-and-function benefit positions retatrutide as the first obesity drug to land both endpoints in a single Phase 3.

#retatrutide #triumph-4 #osteoarthritis #knee-pain #womac #ada-2026
Regulatory

ADA Releases Inaugural Standards of Care in Overweight and Obesity 2026: 34 New Recommendations, Pharmacologic Section, Five Percent Weight-Loss Target

On Saturday June 6, the Obesity Association (a division of the ADA) released the first stand-alone ADA Standards of Care in Overweight and Obesity: 34 new recommendations across seven sections, with a new pharmacologic-treatment section and a target of sustained body-weight reduction of at least 5%. The standards push obesity drugs from off-label discretion into anchored clinical-appropriateness criteria, the framework health systems and payers will use to write coverage policy.

#ada-2026 #obesity-standards-of-care #obesity-association #guidelines #pharmacologic-treatment
Industry

Lilly Retatrutide Seven-Trial Phase 3 Slate Continues Through 2026: OSA, Chronic Low-Back Pain, MASLD, and Cardiometabolic Outcomes Still to Read Out

Beyond TRIUMPH-1 and TRANSCEND-T2D-1, Lilly confirmed at ADA that seven additional Phase 3 retatrutide readouts span obesity, type 2 diabetes, osteoarthritis, obstructive sleep apnea, chronic low-back pain, metabolic dysfunction-associated steatotic liver disease (MASLD), and the cardiometabolic-outcomes program. The MASLD readout is on track for H1 2027, and TRIUMPH-OUTCOMES (cardiovascular events in a 10,000-patient population) anchors the late-2027 timeline.

#retatrutide #eli-lilly #phase-3 #triumph-outcomes #masld #low-back-pain